Computational studies to elucidate the role of proteins in the prevention of malaria

Malaria is a disease that affects half the world's population and is caused by a parasite spread by mosquito. The control of malaria relies on the use of insecticide treated nets to prevent transmission by mosquito bite. Nets alone act as poor barriers to insect bites and the insecticides used to treat the net have a role in killing the insect on contact. As the nets are in frequent contact with people, pyrethroids are the only class of insecticide recommended for use due to its low toxicity to mammals. Insecticide resistance to pyrethroids can occur in insects reducing the effectiveness of the nets to prevent transmission, and insects can become resistant to insecticides by the over expression of cytochrome P450 enzymes. P450 enzymes are a super family of heme containing enzymes involved in the detoxification of drugs and xenobiotics. This study uses computational modelling techniques to give an insight into the structures of the P450s involved in the detoxification of these insecticides. These computational studies complement experimental work and give an understanding of experimental results by giving an insight at the atomic level into the structures of these enzymes. The computational models give explanations for the observed results, but are also predictive and can be used to guide experimental studies. In this study, homology modelling and bioinformatics was used to build structural models of the P450s. These models were validated structurally to ensure that the proteins were correctly folded, docking studies were used to ensure that there was a good correlation between the experimental and computational results. A number of P450s are overexpressed in insecticide resistant mosquitoes these were studied to understand their ability to bind to pyrethroids and comparisons were made to P450s incapable of metabolism. Based on this, a fingerprint for metabolism was constructed that may be used to predict the capacity for metabolism in unknown P450s by identifying residues involved in metabolism. The models produced can be used to explain the profiles of metabolites observed to be produced by these enzymes. The studies on CYP6M2 investigate its ability to metabolise pyrethroids and in particular its metabolism pathway for deltamethrin. It was shown to metabolise deltamethrin at specific sites that can be explained by the models produced in this thesis. The models can also explain the specificity of the enzymes towards a number of fluorescent substrates by identifying the residues that have a steric influence. The models can be used to guide the development of novel pyrethroids that are resistant to metabolism. In addition, the models identified factors external to the active site that influence the metabolism of pyrethroids including its interaction with binding partners and the membrane as well as ligand access to the buried active site. Such factors explain the selectivity of enzymes for the logP of their substrates. These models were used to design probes specific to metabolising enzymes that can be used to identify novel P450s involved in insecticide resistance, and could be used to monitor resistance in insect populations. In the human host, toll like receptors are involved in sensing the malaria parasite and initiate an inflammatory response, an excessive inflammatory response can lead to severe forms of malaria. Mal has a central role in this pathway and the affect of malaria on the human host can be determined by the variant of this protein. Understanding the role of Mal can lead to the identification of targets for drugs that can modulate the immune response and prevent hyper inflammatory disorders.EThOS - Electronic Theses Online ServiceGBUnited Kingdo

Exploring the speed and performance of molecular replacement with AMPLE using QUARK ab initio protein models

Peer Reviewedhttp://deepblue.lib.umich.edu/bitstream/2027.42/110744/1/S1399004714025784.pd

Routine phasing of coiled-coil protein crystal structures with AMPLE

Coiled-coil protein folds are among the most abundant in nature. These folds consist of long wound α-helices and are architecturally simple, but paradoxically their crystallographic structures are notoriously difficult to solve with molecular-replacement techniques. The program AMPLE can solve crystal structures by molecular replacement using ab initio search models in the absence of an existent homologous protein structure. AMPLE has been benchmarked on a large and diverse test set of coiled-coil crystal structures and has been found to solve 80% of all cases. Successes included structures with chain lengths of up to 253 residues and resolutions down to 2.9 Å, considerably extending the limits on size and resolution that are typically tractable by ab initio methodologies. The structures of two macromolecular complexes, one including DNA, were also successfully solved using their coiled-coil components. It is demonstrated that both the ab initio modelling and the use of ensemble search models contribute to the success of AMPLE by comparison with phasing attempts using single structures or ideal polyalanine helices. These successes suggest that molecular replacement with AMPLE should be the method of choice for the crystallographic elucidation of a coiled-coil structure. Furthermore, AMPLE may be able to exploit the presence of a coiled coil in a complex to provide a convenient route for phasing

Identification of 2-Aryl-Quinolone Inhibitors of Cytochrome bd and Chemical Validation of Combination Strategies for Respiratory Inhibitors against Mycobacterium tuberculosis

Mycobacterium tuberculosis cytochrome bd quinol oxidase (cyt bd), the alternative terminal oxidase of the respiratory chain, has been identified as playing a key role during chronic infection and presents a putative target for the development of novel antitubercular agents. Here, we report confirmation of successful heterologous expression of M. tuberculosis cytochrome bd. The heterologous M. tuberculosis cytochrome bd expression system was used to identify a chemical series of inhibitors based on the 2-aryl-quinolone pharmacophore. Cytochrome bd inhibitors displayed modest efficacy in M. tuberculosis growth suppression assays together with a bacteriostatic phenotype in time-kill curve assays. Significantly, however, inhibitor combinations containing our front-runner cyt bd inhibitor CK-2-63 with either cyt bcc-aa3 inhibitors (e.g., Q203) and/or adenosine triphosphate (ATP) synthase inhibitors (e.g., bedaquiline) displayed enhanced efficacy with respect to the reduction of mycobacterium oxygen consumption, growth suppression, and in vitro sterilization kinetics. In vivo combinations of Q203 and CK-2-63 resulted in a modest lowering of lung burden compared to treatment with Q203 alone. The reduced efficacy in the in vivo experiments compared to in vitro experiments was shown to be a result of high plasma protein binding and a low unbound drug exposure at the target site. While further development is required to improve the tractability of cyt bd inhibitors for clinical evaluation, these data support the approach of using small-molecule inhibitors to target multiple components of the branched respiratory chain of M. tuberculosis as a combination strategy to improve therapeutic and pharmacokinetic/pharmacodynamic (PK/PD) indices related to efficacy

Formal Modeling and Analysis of the MAL-Associated Biological Regulatory Network: Insight into Cerebral Malaria

The discrete modeling formalism of René Thomas is a well known approach for the modeling and analysis of Biological Regulatory Networks (BRNs). This formalism uses a set of parameters which reflect the dynamics of the BRN under study. These parameters are initially unknown but may be deduced from the appropriately chosen observed dynamics of a BRN. The discrete model can be further enriched by using the model checking tool HyTech along with delay parameters. This paves the way to accurately analyse a BRN and to make predictions about critical trajectories which lead to a normal or diseased response. In this paper, we apply the formal discrete and hybrid (discrete and continuous) modeling approaches to characterize behavior of the BRN associated with MyD88-adapter-like (MAL) – a key protein involved with innate immune response to infections. In order to demonstrate the practical effectiveness of our current work, different trajectories and corresponding conditions that may lead to the development of cerebral malaria (CM) are identified. Our results suggest that the system converges towards hyperinflammation if Bruton's tyrosine kinase (BTK) remains constitutively active along with pre-existing high cytokine levels which may play an important role in CM pathogenesis

Industrial scale high-throughput screening delivers multiple fast acting macrofilaricides.

Nematodes causing lymphatic filariasis and onchocerciasis rely on their bacterial endosymbiont, Wolbachia, for survival and fecundity, making Wolbachia a promising therapeutic target. Here we perform a high-throughput screen of AstraZeneca's 1.3 million in-house compound library and identify 5 novel chemotypes with faster in vitro kill rates (<2 days) than existing anti-Wolbachia drugs that cure onchocerciasis and lymphatic filariasis. This industrial scale anthelmintic neglected tropical disease (NTD) screening campaign is the result of a partnership between the Anti-Wolbachia consortium (A∙WOL) and AstraZeneca. The campaign was informed throughout by rational prioritisation and triage of compounds using cheminformatics to balance chemical diversity and drug like properties reducing the chance of attrition from the outset. Ongoing development of these multiple chemotypes, all with superior time-kill kinetics than registered antibiotics with anti-Wolbachia activity, has the potential to improve upon the current therapeutic options and deliver improved, safer and more selective macrofilaricidal drugs

Allelic Variation of Cytochrome P450s Drives Resistance to Bednet Insecticides in a Major Malaria Vector

Scale up of Long Lasting Insecticide Nets (LLINs) has massively contributed to reduce malaria mortality across Africa. However, resistance to pyrethroid insecticides in malaria vectors threatens its continued effectiveness. Deciphering the detailed molecular basis of such resistance and designing diagnostic tools is critical to implement suitable resistance management strategies. Here, we demonstrated that allelic variation in two cytochrome P450 genes is the most important driver of pyrethroid resistance in the major African malaria vector Anopheles funestus and detected key mutations controlling this resistance. An Africa-wide polymorphism analysis of the duplicated genes CYP6P9a and CYP6P9b revealed that both genes are directionally selected with alleles segregating according to resistance phenotypes. Modelling and docking simulations predicted that resistant alleles were better metabolizers of pyrethroids than susceptible alleles. Metabolism assays performed with recombinant enzymes of various alleles confirmed that alleles from resistant mosquitoes had significantly higher activities toward pyrethroids. Additionally, transgenic expression in Drosophila showed that flies expressing resistant alleles of both genes were significantly more resistant to pyrethroids compared with those expressing the susceptible alleles, indicating that allelic variation is the key resistance mechanism. Furthermore, site-directed mutagenesis and functional analyses demonstrated that three amino acid changes (Val109Ile, Asp335Glu and Asn384Ser) from the resistant allele of CYP6P9b were key pyrethroid resistance mutations inducing high metabolic efficiency. The detection of these first DNA markers of metabolic resistance to pyrethroids allows the design of DNA-based diagnostic tools to detect and track resistance associated with bednets scale up, which will improve the design of evidence-based resistance management strategies